Hossein Rahnama, CEO of Flybits, a MaRS Innovation spin-off company, appeared on CBC's Lang and O'Leary Exchange on August 24, 2012.
Watch Rahnama's interview on CBC's Media Player. The interview begins at the 13:40 mark and runs to 19:30.
Rahnama, who is also a professor at Ryerson University and and research director at Ryerson's Digital Media Zone, was recently named to the MIT Technology Review’s prestigious 35 Inventors Under 35 list for 2012 along with fellow MaRS Innovation inventor Joyce Poon.
He describes his ...
Raphael Hofstein, president and CEO of MaRS Innovation, was interviewed by Huffington Post Canada business reporter Rachel Mendleson for an article about Canada's innovation gap and the shortage of Canadian venture capital:
One of the best ways to [raise venture capital], said Raphael Hofstein, President and CEO of Toronto-based MaRS Innovation, is to increase government investment, a lesson he learned while helping to create a life sciences early-stage fund in Israel several years ago.
“Everybody told us — institutions, industry — that they ...
Joel Liederman, MaRS Innovation’s vice-president of Business Development and Physical Sciences, was quoted in a National Post article, published August 13, probing whether Canadian research is passing the commercialization test.
Here's an excerpt:
While academics have often been accused of being disconnected from the real world and consuming themselves with the theoretical, it’s hard to imagine they would be able to get away with squandering funding dollars on things that make them go hmmm, particularly in light of the hyper focus on fiscal ...
Xagenic’s financing round to test platform and first diagnostic assay, continue product development and begin FDA submission
Toronto, ON (December 2, 2013) — MaRS Innovation’s first start-up company, Xagenic Inc., is developing the first lab-free molecular diagnostic platform with a 20-minute time-to-result based on University of Toronto research by Professors Shana Kelley and Edward Sargent.
Today, Xagenic announced it has successfully closed a Series B financing round totaling $20 million. New investor Domain Associates, LLC, led the round, joined by existing investors who ...
MaRS Innovation's President and CEO, Raphael Hofstein, has published an editorial outlining the challenges facing entrepreneurs seeking to bring new healthcare innovations to market for the National Post's Medical Devices supplement.
The article, titled "Investing in innovation for a healthier Canada," is available on page 2 of the Post supplement.
Posted by Elizabeth Monier-Williams, marketing and communications officer.
Joel Liederman, MaRS Innovation's vice-president of Business Development and Physical Sciences, is participating in a live chat on the Financial Post's website.
The chat will take place on June 28, 2012 at 2 pm.
Topic: Why Canada can't do anything with its big ideas
When it comes to academic research and the development or discovery of new concepts or product models, there are few countries in the world that can hold a candle to Canada. (more…)
TORONTO, Ontario, Canada – October 24, 2011 – DLVR Therapeutics Inc. (“DLVR”) - a privately-held biotechnology company currently focused on developing oncology therapeutics based on its proprietary high density lipoprotein-like nanoparticle - announced today that the company has completed its seed round investment bringing the total raised to $2 million in cash and in-kind support. MaRS Innovation joins the University Health Network (UHN) and the Ontario Institute for Cancer Research (OICR) as investors in the company. The additional funds will be ...
Dr. Raphael Hofstein, president and CEO of MaRS Innovation, spoke to the Canadian International Council about the importance of protecting intellectual property as an important component in commercializing Canadian technologies.
Here's an excerpt:
Government could be extremely helpful if they created special funds dedicated to covering the costs of patent protection.
Provincial Investment Supports Commercialization of Leading-Edge Molecular Diagnostic Screening Technology
TORONTO (July 26, 2011) — Xagenic Inc., one of MaRS Innovation’s (MI) portfolio spin-off companies, was awarded $1 million in funding by Ontario’s Ministry of Research and Innovation (MRI) through its Investment Accelerator Fund‐Life Sciences (IAF-LS) program.
Research and Innovation Minister Glen Murray made the announcement at MaRS Discovery District.
“Today’s announcement will go a long way in helping us to commercialize a technology that will ultimately shape the future of diagnostic testing — instead ...
TORONTO (May 31, 2011) — MaRS Innovation (MI) and GlaxoSmithKline Inc. (GSK) today announced a new development fund — the GSK-MaRS Innovation Fund — that will support and fast-track the commercialization of some of the country’s most promising translational research coming from 16 leading academic health sciences centres, hospitals and universities derived from MI’s member institutions.
“From the discovery of insulin in 1922 to the discovery of stem cells, Ontario has a rich, proud history of world-class medical and scientific breakthroughs,” said ...